Standardized MRI and Molecular Imaging Reporting for Focal Therapy Follow-up – Creating Imaging Based Short and Intermediate Outcomes
Daniel Margolis, MD, focuses on standardized MRI and molecular imaging reporting for follow-up in prostate cancer focal therapy. Implementing standardized protocols for imaging evaluation post-focal therapy aims to ensure consistency and reliability across different healthcare settings, facilitate accurate comparison of treatment outcomes, and enable evidence-based decision-making.
Multiparametric MRI (mpMRI) is a cornerstone of the follow-up strategy. By utilizing standardized reporting systems such as the Prostate Imaging Reporting and Data System (PI-RADS), radiologists can systematically assess post-treatment changes, detect residual or recurrent disease, and monitor treatment response. Dr. Margolis also discusses molecular imaging techniques that offer additional insights into treatment response and disease activity at a molecular level. Novel tracers and imaging agents target specific biological markers associated with prostate cancer, enhancing the precision and sensitivity of post-treatment assessments.
Dr. Margolis emphasizes the importance of integrating these imaging modalities into a cohesive framework. This approach not only aids in the early detection of treatment failure or disease recurrence but also guides timely intervention and adjustment of therapeutic strategies.
